Literature DB >> 30702538

Exploring Emergency Department Provider Experiences With and Perceptions of Weight-Based Versus Individualized Vaso-Occlusive Treatment Protocols in Sickle Cell Disease.

LaʼKita M J Knight1, Elijah O Onsomu, Hayden B Bosworth, Regina D Crawford, Theresa DeMartino, Jeffrey Glassberg, Judith A Paice, Christopher N Miller, Lynne Richardson, Paula Tanabe.   

Abstract

Treatment of vaso-occlusive episodes (VOEs) is the most common reason for emergency department (ED) treatment of sickle cell disease (SCD). We (1) compared perceptions of the usability and ability to manage VOE pain between ED nurses and other ED provider types, ED sites, and VOE protocols (individualized vs. weight-based), and (2) identified ED nurse and other provider protocol suggestions. A secondary analysis of provider survey data collected immediately after caring for a patient enrolled in a randomized controlled trial comparing weight-based versus individualized opioid dosing for VOE. Research staff asked the ED nurses and other ED providers (nurse practitioners [NPs], physician assistants [PAs], residents, and attending physicians) 5 questions related to the protocol's ease of use and ability to manage pain. There were 236 surveys completed. Attending physicians (n = 15), residents (n = 88), PAs (n = 21), and NPs (n = l) were more satisfied than nurses (n = 111) with the clarity of the analgesic ordering (97.6% vs. 0%, p = 0.0001) and ability to manage the patient's VOE pain (91% vs. 0%, p = 0.0001). When comparing both protocols with the usual ED strategy in their ED to manage VOE, more nurses than other ED providers perceived the study patients' pain management protocol as better (100% vs. 35.2%, p = 0.0001). Other ED providers perceived the individualized versus weight-based protocol as better at managing pain than their usual ED strategy (70.3% vs. 59.5%, p = 0.04). The individualized protocol was perceived as better in managing VOE than the weight-based ED strategy. While physicians were satisfied with the clarity of the protocols, nurses were not. Improved protocol usability is required for widespread ED implementation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30702538      PMCID: PMC6361535          DOI: 10.1097/TME.0000000000000232

Source DB:  PubMed          Journal:  Adv Emerg Nurs J        ISSN: 1931-4485


  8 in total

1.  Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department.

Authors:  Patricia L Kavanagh; Philippa G Sprinz; Tahlia L Wolfgang; Kelly Killius; Maria Champigny; Amy Sobota; David Dorfman; Karan Barry; Renee Miner; James M Moses
Journal:  Pediatrics       Date:  2015-09-21       Impact factor: 7.124

2.  The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database.

Authors:  Sophie Lanzkron; C Patrick Carroll; Carlton Haywood
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

3.  Sickle cell disease in California: sociodemographic predictors of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Rachna Khanna; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

4.  A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD).

Authors:  Paula Tanabe; Susan Silva; Hayden B Bosworth; Regina Crawford; Judith A Paice; Lynne D Richardson; Christopher N Miller; Jeffrey Glassberg
Journal:  Am J Hematol       Date:  2017-11-10       Impact factor: 10.047

5.  Impact of individualized pain plan on the emergency management of children with sickle cell disease.

Authors:  Lakshmanan Krishnamurti; Bethanny Smith-Packard; Ashish Gupta; Mary Campbell; Sriya Gunawardena; Richard Saladino
Journal:  Pediatr Blood Cancer       Date:  2014-06-24       Impact factor: 3.167

6.  Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? a mixed methods evaluation.

Authors:  Yi-Chin Kato-Lin; Lakshmanan Krishnamurti; Rema Padman; Howard J Seltman
Journal:  Int J Med Inform       Date:  2014-08-17       Impact factor: 4.046

7.  Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.

Authors:  Sophie Lanzkron; Carlton Haywood; Kathryn L Hassell; Cynthia Rand
Journal:  J Natl Med Assoc       Date:  2008-08       Impact factor: 1.798

8.  Use of a clinical pathway to improve the acute management of vaso-occlusive crisis pain in pediatric sickle cell disease.

Authors:  Katherine L Ender; Jennifer A Krajewski; John Babineau; Mary Tresgallo; William Schechter; John M Saroyan; Anupam Kharbanda
Journal:  Pediatr Blood Cancer       Date:  2013-11-19       Impact factor: 3.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.